Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rapid virus test aims to slash needless antibiotic prescriptions

NCT ID NCT07243249

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 2 times

Summary

This study tests whether a rapid nose swab test that detects three common respiratory viruses (COVID-19, flu, and RSV) can help doctors avoid prescribing antibiotics when they aren't needed. About 2,000 people with respiratory symptoms will be enrolled. Doctors will either prescribe antibiotics as usual or use the test results to guide their decision. The goal is to see if the test reduces unnecessary antibiotic use, which can lead to antibiotic resistance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Triplex rapid diagnostic test (TROD) for SARS-CoV-2, influenza, and RSV
What this could lead to
If successful, this could show that rapid virus testing helps doctors avoid unnecessary antibiotics, reducing antibiotic resistance.
What could go wrong
This is an observational study, not a treatment trial. Results may not change prescribing habits in all settings, and the test may not catch all infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 1 year 2. Presenting with: * Either fever (temperature \> 38°C measured by patient or physician) within the past 72 hours, and one of the following symptom combinations: 1. Rhinorrhea (white, yellow, or green discharge) and/or nasal obstruction, and cough 2. Body aches, cough, and fatigue 3. Odynophagia and negative strepto-test 4. Cough 5. Otalgia * Or suspicion of lower respiratory tract infection: signs of infection (respiratory rate \> 20/min, heart rate \> 100/min, fatigue, Body aches, chills, or fever), associated with pulmonary localization signs \[cough, sputum, chest pain, auscultatory abnormality (rhonchi, crackles, or wheezing)\] 3. Affiliation with the national health insurance system 4. Informed consent obtained from the adult participant, or from the person(s) with parental authority for a minor participant Exclusion Criteria: 1. Requirement for hospitalization 2. Presence of a non-respiratory infection requiring concomitant antibiotic treatment. 3. Patients covered by State Medical Aid (AME)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antibiotic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

respiratory tract infectious disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antibiotic Respiratory infections

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assistance Publique - Hôpitaux de Paris

    RECRUITING

    Garches, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.